Strong data on Ofev in IPF backs Boehringer's claims on respiratory diseases
Long-term data has shown the beneficial effect of Boehringer Ingelheim’s approved treatment Ofev (nintedanib) in idiopathic pulmonary fibrosis (IPF).
It is the third set of data presented by the privately-held Germany company around the European Respiratory Society (ERS) International Congress 2016 this week, after it announced progress with treatments for asthma and chronic obstructive pulmonary disease (COPD) treatments too.
Boehringer presented eight IPF-related abstracts at the Congress, including new interim data from the INPULSIS-ON extension trial assessing long-term treatment with Ofev on patients with what is a chronic, debilitating and fatal lung disease with high mortality and a median life expectancy after diagnosis of approximately two to three years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze